Skip to main content
Top
Published in: Annals of Hematology 7/2012

01-07-2012 | Original Article

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Authors: Qitian Mu, Qiuling Ma, Yungui Wang, Zhimei Chen, Xiangmin Tong, Fei-Fei Chen, Ying Lu, Jie Jin

Published in: Annals of Hematology | Issue 7/2012

Login to get access

Abstract

Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center in China. Of 1,266 newly diagnosed CML patients, the median age was 41 years, which is younger than the median age of diagnosis in western populations. The incidence of additional chromosome abnormalities (ACA) was 3.1% in newly diagnosed chronic phase (CP), 9.1% in CP after therapy, 35.4% in accelerated phase, and 52.9% in blast crisis (BC), reflecting cytogenetic evolution with CML progression. A higher prevalence of ACA was observed in variant Ph translocations than in standard t(9;22) in the disease progression, especially in BC (88.2% vs. 50%, P = 0.002). Moreover, a hyperdiploid karyotype and trisomy 8 were closely correlated with myeloid BC, while a hypodiploid karyotype and monosomy 7 were associated with lymphoid-BC. Among subsets of myeloid-BC, myeloid-BC with minimal differentiation had a higher ACA rate than myeloid-BC with granulocytic differentiation (80% vs. 46.8%, P = 0.009) and myeloid-BC with monocytic differentiation (80% vs. 42.9%, P = 0.006). These data provide novel insights into cytogenetics of CML within the Chinese population.
Literature
1.
go back to reference Quintas-Cardama A, Cortes JE (2006) Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81:973–988PubMedCrossRef Quintas-Cardama A, Cortes JE (2006) Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81:973–988PubMedCrossRef
2.
go back to reference Benneriah Y, Daley GQ, Mesmasson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia specific P210-protein is the product of the Bcr/Abl hybrid gene. Science 233:212–214CrossRef Benneriah Y, Daley GQ, Mesmasson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia specific P210-protein is the product of the Bcr/Abl hybrid gene. Science 233:212–214CrossRef
3.
go back to reference Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Groffen J, Heisterkamp N (1995) Bcr/Abl P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603–4611PubMedCrossRef Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Groffen J, Heisterkamp N (1995) Bcr/Abl P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603–4611PubMedCrossRef
5.
go back to reference Ch'ang HJ, Tien HF, Wang CH et al (1993) Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 71:87–93PubMedCrossRef Ch'ang HJ, Tien HF, Wang CH et al (1993) Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 71:87–93PubMedCrossRef
6.
go back to reference Krulik M, Smadja N, Degramont A et al (1987) Sequential karyotype study on Ph-positive chronic myelocytic-leukemia—significance of additional chromosomal-abnormalities during disease evolution. Cancer 60:974–979PubMedCrossRef Krulik M, Smadja N, Degramont A et al (1987) Sequential karyotype study on Ph-positive chronic myelocytic-leukemia—significance of additional chromosomal-abnormalities during disease evolution. Cancer 60:974–979PubMedCrossRef
7.
go back to reference Michalova K, Musilova J, Koudelova Z, Placerova J, Matuchova L (1988) Cytogenetic study of chronic myeloid leukemia. Neoplasma 35:571–581PubMed Michalova K, Musilova J, Koudelova Z, Placerova J, Matuchova L (1988) Cytogenetic study of chronic myeloid leukemia. Neoplasma 35:571–581PubMed
8.
go back to reference Reid AG, De Melo VA, Elderfield K et al (2009) Phenotype of blasts in chronic myeloid leukemia in blastic phase-analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk Res 33:418–425PubMedCrossRef Reid AG, De Melo VA, Elderfield K et al (2009) Phenotype of blasts in chronic myeloid leukemia in blastic phase-analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk Res 33:418–425PubMedCrossRef
9.
go back to reference Parreira L, Kearney L, Rassool F et al (1986) Correlation between chromosomal-abnormalities and blast phenotype in the blast crisis of Ph-positive Cgl. Cancer Genet Cytogenet 22:29–34PubMedCrossRef Parreira L, Kearney L, Rassool F et al (1986) Correlation between chromosomal-abnormalities and blast phenotype in the blast crisis of Ph-positive Cgl. Cancer Genet Cytogenet 22:29–34PubMedCrossRef
10.
go back to reference Lippert E, Etienne G, Mozziconacci MJ et al (2010) Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 95:1604–1607PubMedPubMedCentralCrossRef Lippert E, Etienne G, Mozziconacci MJ et al (2010) Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 95:1604–1607PubMedPubMedCentralCrossRef
11.
go back to reference Cheng Y, Wang Y, Wang H et al (2009) Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia 23:1801–1806PubMedCrossRef Cheng Y, Wang Y, Wang H et al (2009) Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia 23:1801–1806PubMedCrossRef
12.
go back to reference Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497 Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497
13.
go back to reference Rowley JD (1973) New consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293PubMedCrossRef Rowley JD (1973) New consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293PubMedCrossRef
14.
go back to reference Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22:295–302PubMedCrossRef Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22:295–302PubMedCrossRef
15.
go back to reference Rohrbacher M, Berger U, Hochhaus A et al (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23:602–604PubMedCrossRef Rohrbacher M, Berger U, Hochhaus A et al (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23:602–604PubMedCrossRef
16.
go back to reference Tardieu S, Brun-Strang C, Berthaud P et al (2005) Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 14:545–553PubMedCrossRef Tardieu S, Brun-Strang C, Berthaud P et al (2005) Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 14:545–553PubMedCrossRef
17.
18.
go back to reference Weng HH, Tsai SS, Chiu HF, Wu TN, Yang CY (2008) Association of childhood leukemia with residential exposure to petrochemical air pollution in Taiwan. Inhal Toxico 2:31–36CrossRef Weng HH, Tsai SS, Chiu HF, Wu TN, Yang CY (2008) Association of childhood leukemia with residential exposure to petrochemical air pollution in Taiwan. Inhal Toxico 2:31–36CrossRef
19.
go back to reference Yu CL, Wang SF, Pan PC et al (2009) Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol 164:200–207CrossRef Yu CL, Wang SF, Pan PC et al (2009) Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol 164:200–207CrossRef
20.
go back to reference Wong CM, Vichit-Vadakan N, Kan H, Qian Z (2008) Public Health and Air Pollution in Asia (PAPA): a multicity study of short-term effects of air pollution on mortality. Environ Health Perspect 116:1195–1202PubMedPubMedCentralCrossRef Wong CM, Vichit-Vadakan N, Kan H, Qian Z (2008) Public Health and Air Pollution in Asia (PAPA): a multicity study of short-term effects of air pollution on mortality. Environ Health Perspect 116:1195–1202PubMedPubMedCentralCrossRef
21.
go back to reference Bennour A, Sennana H, Laatiri MA, Elloumi M, Khelif A, Saad A (2009) Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9. Cancer Genet Cytogenet 194:30–37PubMedCrossRef Bennour A, Sennana H, Laatiri MA, Elloumi M, Khelif A, Saad A (2009) Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9. Cancer Genet Cytogenet 194:30–37PubMedCrossRef
22.
go back to reference Lowenberg B, Hagemeijer A, Abels J (1985) Detection of the blastic crisis cell clone in chronic myeloid-leukemia. Br J Haematol 59:27–36PubMedCrossRef Lowenberg B, Hagemeijer A, Abels J (1985) Detection of the blastic crisis cell clone in chronic myeloid-leukemia. Br J Haematol 59:27–36PubMedCrossRef
23.
go back to reference Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11(Suppl 1):11–15PubMedCrossRef Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11(Suppl 1):11–15PubMedCrossRef
24.
go back to reference Kantarjian HM, Keating MJ, Talpaz M et al (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83:445–454PubMedCrossRef Kantarjian HM, Keating MJ, Talpaz M et al (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83:445–454PubMedCrossRef
26.
go back to reference Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D (2006) t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 106:1730–1738PubMedCrossRef Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D (2006) t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 106:1730–1738PubMedCrossRef
27.
go back to reference Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94PubMedCrossRef Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94PubMedCrossRef
28.
go back to reference Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM (1996) Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14:196–203PubMedCrossRef Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM (1996) Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14:196–203PubMedCrossRef
29.
go back to reference O'Dwyer ME, Mauro MJ, Kurilik G et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628–1633PubMedCrossRef O'Dwyer ME, Mauro MJ, Kurilik G et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628–1633PubMedCrossRef
30.
go back to reference O'Dwyer ME, Mauro MJ, Blasdel C et al (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103:451–455PubMedCrossRef O'Dwyer ME, Mauro MJ, Blasdel C et al (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103:451–455PubMedCrossRef
31.
go back to reference Verma D, Kantarjian H, Shan J et al (2010) Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116:2673–2681PubMedPubMedCentral Verma D, Kantarjian H, Shan J et al (2010) Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116:2673–2681PubMedPubMedCentral
32.
go back to reference Fabarius A, Leitner A, Hochhaus A et al (2010) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood 118:6760–6768CrossRef Fabarius A, Leitner A, Hochhaus A et al (2010) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood 118:6760–6768CrossRef
33.
go back to reference El-Zimaity MM, Kantarjian H, Talpaz M et al (2004) Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125:187–195PubMedCrossRef El-Zimaity MM, Kantarjian H, Talpaz M et al (2004) Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125:187–195PubMedCrossRef
34.
go back to reference Gorusu M, Benn P, Li ZH, Fang M (2007) On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 173:97–106PubMedCrossRef Gorusu M, Benn P, Li ZH, Fang M (2007) On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 173:97–106PubMedCrossRef
35.
go back to reference Sinclair PB, Nacheva EP, Leversha M et al (2000) Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95:738–743PubMedCrossRef Sinclair PB, Nacheva EP, Leversha M et al (2000) Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95:738–743PubMedCrossRef
36.
go back to reference Huntly BJ, Reid AG, Bench AJ et al (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98:1732–1738PubMedCrossRef Huntly BJ, Reid AG, Bench AJ et al (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98:1732–1738PubMedCrossRef
37.
go back to reference Marzocchi G, Castagnetti F, Luatti S et al (2011) Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis. Blood 117:6793–6800PubMedCrossRef Marzocchi G, Castagnetti F, Luatti S et al (2011) Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis. Blood 117:6793–6800PubMedCrossRef
38.
go back to reference Diezmartin JL, Dewald GW, Pierre RV (1988) Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic-leukemia. Am J Hematol 27:194–203CrossRef Diezmartin JL, Dewald GW, Pierre RV (1988) Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic-leukemia. Am J Hematol 27:194–203CrossRef
39.
go back to reference Nacheva EP, Brazma D, Virgili A et al (2010) Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. Bmc Genomics 11:41PubMedPubMedCentralCrossRef Nacheva EP, Brazma D, Virgili A et al (2010) Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. Bmc Genomics 11:41PubMedPubMedCentralCrossRef
40.
go back to reference Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T (2005) Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol 84:785–791PubMedCrossRef Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T (2005) Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol 84:785–791PubMedCrossRef
41.
go back to reference Bene MC, Bernier M, Casasnovas RO et al (2001) Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 113:737–745PubMedCrossRef Bene MC, Bernier M, Casasnovas RO et al (2001) Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 113:737–745PubMedCrossRef
Metadata
Title
Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population
Authors
Qitian Mu
Qiuling Ma
Yungui Wang
Zhimei Chen
Xiangmin Tong
Fei-Fei Chen
Ying Lu
Jie Jin
Publication date
01-07-2012
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1421-6

Other articles of this Issue 7/2012

Annals of Hematology 7/2012 Go to the issue